Immutep (IMMP) FCF Margin (2011 - 2017)

Immutep (IMMP) posted FCF Margin of 259.22% for Q2 2017, up 94.51% on a QoQ basis from 4719.96% in Q2 2016, and up 446074.0% year-over-year from N/an in Q2 2016.

Immutep (IMMP) FCF Margin (2011 - 2017) Analysis & Trends

Immutep's FCF Margin history runs 5 years deep, the most recent figure standing at 259.22% for Q2 2017.

  • Quarterly FCF Margin rose 446074.0% year-over-year to 259.22% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 423.74% (down 42231.0% YoY) and the FY2025 annual result came in at 601.04%, down 15644.0% from the prior year.
  • FCF Margin was 259.22% for Q2 2017 at Immutep, up from 4719.96% in the prior quarter.
  • Across five years, FCF Margin topped out at 110.43% in Q2 2014 and bottomed at 4719.96% in Q2 2016.
  • A 4-year average of 1217.34% and a median of 129.9% in 2015 frame the typical range for FCF Margin.
  • Annual changes were most pronounced in 2016 — FCF Margin slumped 471937 bps — and 2017, when it soared 446074 bps.
  • Immutep's FCF Margin stood at 110.43% in 2014, then sank by 101 bps to 0.59% in 2015, then tumbled by 800605 bps to 4719.96% in 2016, then jumped by 95 bps to 259.22% in 2017.
  • Business Quant data shows IMMP's FCF Margin at 259.22% in Q2 2017, 4719.96% in Q2 2016, and 0.59% in Q2 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 10.45%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 43.35%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 23.53%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Immutep 569.08 Mn 569.08 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2017 -259.22%
Jun 30, 2016 -4,719.96%
Jun 30, 2015 -0.59%
Jun 30, 2014 110.43%
Jun 30, 2011 61.01%